PMID- 35700643
OWN - NLM
STAT- MEDLINE
DCOM- 20220804
LR  - 20220821
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 439
DP  - 2022 Aug 15
TI  - Review of potential psychedelic treatments for PTSD.
PG  - 120302
LID - S0022-510X(22)00164-2 [pii]
LID - 10.1016/j.jns.2022.120302 [doi]
AB  - Post-traumatic stress disorder (PTSD) is a debilitating mental illness with 
      limited treatment options and a high treatment dropout rate. Psychedelics, often 
      in combination with psychotherapy, are now under investigation as a potential 
      treatment option for a variety of psychiatric conditions including PTSD. This 
      paper reviews the proposed mechanism of action for 
      3,4-Methylenedioxymethamphetamine (MDMA) and classical psychedelics such as 
      psilocybin in treating PTSD, along with available clinical evidence, safety and 
      side effects. MDMA-assisted psychotherapy is in FDA phase III clinical trials for 
      PTSD and is purported to work by way of increased empathy and decreased amygdala 
      activation during the therapeutic encounter and trauma processing. Classical 
      psychedelics may create change by a subjective transformative experience along 
      with an observable process of brain network alterations, though these substances 
      have not been clinically studied in the context PTSD. In recent human-subject 
      studies MDMA-assisted therapy resulted in significant improvement in PTSD 
      symptoms with a good safety and side effect profile. There is not yet direct 
      clinical evidence for classical psychedelics in treating PTSD, but the evidence 
      supports such a trial. The studies to date have been relatively small, and 
      participants are wellscreened for potential co-morbidities which could increase 
      the risks of psychedelic treatment. Nonetheless, the data is promising for 
      psychedelic-assisted treatment to become a much-needed treatment option for PTSD.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Henner, Ryan L
AU  - Henner RL
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA; Beth Israel 
      Deaconess Medical Center, Boston, MA, USA. Electronic address: 
      rhenner@bidmc.harvard.edu.
FAU - Keshavan, Matcheri S
AU  - Keshavan MS
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA; Beth Israel 
      Deaconess Medical Center, Boston, MA, USA; Beth Israel Deaconess Medical Center, 
      Massachusetts Mental Health Center, Boston, MA, USA.
FAU - Hill, Kevin P
AU  - Hill KP
AD  - Division of Addiction Psychiatry, Beth Israel Deaconess Medical Center, Boston, 
      MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220530
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Combined Modality Therapy
MH  - *Hallucinogens/therapeutic use
MH  - Humans
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/adverse effects
MH  - Psychotherapy/methods
MH  - *Stress Disorders, Post-Traumatic/drug therapy
OTO - NOTNLM
OT  - 3,4-Methylenedioxymethamphetamine
OT  - MDMA
OT  - PTSD
OT  - Post-traumatic stress disorder
OT  - Psilocin
OT  - Psilocybin
OT  - Psychedelic
OT  - Psychedelic-assisted therapy
EDAT- 2022/06/15 06:00
MHDA- 2022/08/05 06:00
CRDT- 2022/06/14 18:20
PHST- 2021/05/26 00:00 [received]
PHST- 2022/04/27 00:00 [revised]
PHST- 2022/05/24 00:00 [accepted]
PHST- 2022/06/15 06:00 [pubmed]
PHST- 2022/08/05 06:00 [medline]
PHST- 2022/06/14 18:20 [entrez]
AID - S0022-510X(22)00164-2 [pii]
AID - 10.1016/j.jns.2022.120302 [doi]
PST - ppublish
SO  - J Neurol Sci. 2022 Aug 15;439:120302. doi: 10.1016/j.jns.2022.120302. Epub 2022 
      May 30.